Clinical Trials/ACTRN12619000115134

ACTRN12619000115134

Suspended

未知

A multi-centre, patient and assessor-blinded, parallel groups, randomised controlled trial comparing restricted and liberal oxygen therapy with standard oxygen therapy in patients having major surgery

Medical Research Institute of New Zealand0 sites2,640 target enrollmentJanuary 25, 2019

ConditionsHyperoxia, hyperoxaemia Major non-cardiac surgery Surgical site infection Postoperative complications Anaesthesiology - Anaesthetics

Overview

Phase: 未知
Intervention: Not specified
Conditions: Hyperoxia, hyperoxaemia
Sponsor: Medical Research Institute of New Zealand
Enrollment: 2640
Status: Suspended
Last Updated: 3 years ago

Overview Investigators Eligibility Criteria Outcomes Similar Trials

Overview

Brief Summary

No summary available.

Registry

who.int

Start Date

January 25, 2019

End Date

TBD

Last Updated

3 years ago

Study Type

Interventional

Sex

All

Investigators

Sponsor

Medical Research Institute of New Zealand

Eligibility Criteria

Inclusion Criteria

•Patients undergoing non\-cardiac surgery under general anaesthesia with an expected duration of at least 2 hours and anticipated in\-hospital stay of at least 1 post\-operative night
•American Society of Anaesthesiologists Physical Status Classification (ASA) 3 or 4

Exclusion Criteria

•Current pregnancy
•The treating clinicians consider that there is a specific indication for either liberal or restricted oxygen therapy in the perioperative period
•Previously enrolled in the HOT\-ROX study

Outcomes

Primary Outcomes

Not specified

Similar Trials

Comparison of efficacy and safety of Betesil® medicated plaster versus Daivobet®/Dovobet® ointment in the treatment of chronic plaque psoriasisChronic plaque psoriasisSkin and Connective Tissue DiseasesPsoriasis

ISRCTN34974208Institut Biochimique SA (IBSA) (Switzerland)300

Efficacy and safety of Institut Biochimique SA (IBSA) 0.1% betamethasone valerate (BMV) medicated plaster versus reference marketed product for the treatment of chronic plaque psoriasis

ISRCTN68864186Institut Biochimique SA (IBSA) (Switzerland)180

Active, not recruiting

Multicentre, prospective, assessor-blind, in parallel groups randomised and vs reference marketed product controlled confirmatory trial of the efficacy and safety of IBSA BMV medicated plaster for the treatment of chronic plaque psoriasischronic plaque psoriasisMedDRA version: 9.1Level: LLTClassification code 10033898Term: Parapsoriasis

EUCTR2005-003050-96-ITIBSA180

Active, not recruiting

Multicentre, prospective, assessor-blind, in parallel groups randomised and controlled trial of the efficacy and safety of betamethasone valerate 2.25mg medicated plaster (Betesil, IBSA-Institut Biochimique S.A.) versus 50μg-0,5mg/g calcipotriol-betamethasone (dipropionate) ointment (Daivobet/Dovobet, LEO Pharmaceutical Products), in the treatment of chronic plaque psoriasis. - ND

EUCTR2009-016969-28-ITIBSA INSTITUT BIOCHIMIQUE SA300

Active, not recruiting

Multicentre, prospective, assessor-blind, in parallel groups randomised and controlled trial of the efficacy and safety of betamethasone valerate 2.25mg medicated plaster (Betesil®, IBSA-Institut Biochimique S.A.) versus 50µg-0,5mg/g calcipotriol-betamethasone (dipropionate) ointment (Daivobet®/Dovobet®, LEO Pharmaceutical Products), in the treatment of chronic plaque psoriasis.

EUCTR2009-016969-28-FRIBSA, Institut Biochimique SA